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1. Introduction 
Taenia solium cysticercosis is a major public health and agricultural problem in many 
developing countries. It is predominantly found and considered endemic in Latin American, 
Asian, and African countries where pigs are raised using traditional methods, veterinary 
meat inspection is insufficient, and sanitation is poor [1-3]. However, it is now increasingly 
being diagnosed in other regions such as the United States, Western Europe, and Canada 
due to an increasing flow of immigrants from endemic areas who may have taeniasis or 
cysticercosis [4-7]. The parasite not only impacts human health, but also pig farmers and 
their communities. In humans, the larvae of the parasite (metacestodes) may migrate to the 
brain resulting in neurocysticercosis (NCC). The natural history of NCC infection remains 
poorly understood, and the proportion of cases with lesions in their brains that will manifest 
at some point during the course of the infection remains unknown. According to a recent 
systematic review of the literature, among diagnosed NCC patients who sought care in 
clinics where imaging was available, epileptic seizures were by far the most common 
presenting symptom, followed by headaches, focal deficits, and cranial 
hypertension/hydrocephalus [8]. Depression has been reported to be very common among 
NCC patients, but it has not been determined if this is due to the presence of epilepsy or 
NCC itself [9]. Other manifestations of NCC include stroke and dementia, but those aspects 
have been very poorly described [10, 11]. The social consequences of NCC possibly include 
stigmatization, incapacitation, and decreased work productivity. Epilepsy has been shown, 
in several countries, to lead to social discrimination, and NCC-associated epilepsy is no 
different. In many endemic countries, the stigma associated with epilepsy may have a 
greater impact on patients’ lives and families than the disease itself [12]. In addition, due to 
the reduction in quality of life and the psychological effects of the condition, work 
productivity might be further decreased. 
In pigs, infection with the larval stages of the parasite results in the development of cysts 
primarily in the muscles, and less commonly in the tongue muscles, heart, diaphragm, 
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brain, and other organ systems. The presence of these cysts can lead to partial or full 
condemnation of the carcass and economic losses in areas where meat is inspected. In some 
areas, pig traders look for the presence of cysts under the tongue before buying them, and 
will offer a lower price for animals affected. This parasite, therefore, can reduce the 
household income of farmers and whole communities that share the same environment. 
Porcine cysticercosis is most commonly associated with small holder farming practices and 
is often under-reported due to the absence of clinical signs in affected pigs and lack of meat 
inspection facilities and expertise in endemic countries. 
Because cysticercosis impacts human and pig heath and results in economic losses, there is a 
need to evaluate the socioeconomic impact, or burden, of this condition on endemic 
communities. Both non-monetary and monetary methods can be employed. These estimates 
may then be compared among diseases to better target which diseases to control. Disease 
burden estimates can subsequently be used to compare alternative control strategies for 
cysticercosis, as well as other diseases affecting the population, through cost-utility and cost-
benefit analyses. These analyses can guide stakeholders as to which diseases and control 
strategies should be prioritized to reduce the burden of diseases in the population.  
2. Methods for evaluation of the burden of zoonotic infections 
Taenia solium cysticercosis results in mortality, morbidity, and economic losses in affected 
human and animal populations. To evaluate the burden of cysticercosis, the monetary and 
non-monetary impacts of the disease on human health, agriculture, and society must be 
considered comprehensively. Measuring burden is challenging because it requires various 
types of data from valid studies conducted in humans and pig populations. Because of those 
challenges, it is recommended to focus the evaluation on a certain period and to one 
geographical area where high quality epidemiological and clinical studies have been 
conducted, preferably in both pigs and humans. The disadvantage of such an approach is 
that the data cannot be generalized to other areas. Some data are required for the estimation 
of both the non-monetary and the monetary burden of cysticercosis. In humans, these data 
include: the death rate of NCC (the number of deaths, if available, can also be used); the 
proportion of patients with NCC who seek care in clinics (and hospitals); the number (or 
incidence rate) of cases of NCC diagnosed after care has been sought; and the frequency and 
duration of each NCC manifestation. In pigs, the data required include the proportion of 
pigs that are inspected pre or post-mortem and the proportion of infected pigs diagnosed 
pre or post-mortem. Such data may be found in the published/unpublished literature and 
national or regional databases. When some aspects of the data are unavailable, opinion of 
local experts may be sought and uncertainty analyses can be run. In estimating the burden 
of NCC, there is the additional challenge that the internationally recognized definition of 
NCC requires the use of diagnostic imaging (computed tomography (CT) scan or magnetic 
resonance imaging (MRI)), autopsy or biopsy of skin nodules [13]. The absence of advanced 
diagnostic imaging facilities limits the evaluation of the burden of NCC in many areas of the 
world, and especially in the poorest regions where the disease is likely to be most prevalent. 
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Serological tests are designed to measure the exposure to, or current infection with, 
cysticercosis [14], but can show low specificity and sensitivity in the diagnosis of NCC, 
depending on the number and stages of lesions present in the brain [15]. 
3. Measuring the non-monetary burden of cysticercosis 
Specific measures have been designed to estimate the non-monetary burden of human 
diseases [16, 17]. We will not discuss here measures of mortality and morbidity that can also 
be used in animals. The most informative measure of non-monetary burden is believed to be 
“utility”, an economical concept which has been adapted to health economics, and measures 
the preference that people have for certain health status along a continuum [18].The greater 
the preference for a particular health state, the greater the "utility" associated with it. Several 
Health Adjusted Life Years (HALYs) metrics have been developed as indicators of “utility”. 
HALYs are summary measures of population health that enable measures of mortality to be 
combined with measures of disability associated with each sequela (manifestation) of the 
disease of interest into one metric. 
There are two types of HALYs that have been commonly used in estimating human burden 
of disease: Quality Adjusted Life Years (QALYs) and Disability Adjusted Life Years 
(DALYs). Even though QALYs and DALYs may be used to estimate utilities, they were 
developed to serve different purposes. Where DALYs are meant as an objective, population-
based measure, QALYs are meant to be used as a subjective, individual-based measure of 
utility and health. In addition, these measures use opposite scales. The DALY is a negative 
concept, with one DALY being the equivalent of one year lived completely disabled 
(analogous to death) whereas the QALY is a positive concept, with one QALY being the 
equivalent of one year of healthy life [18]. Therefore, control strategies would aim to 
minimize DALYs and maximize QALYs. 
3.1. Quality Adjusted Life Years (QALYs) 
The ideal way of measuring quality of life is to attribute a utility, or a weighted preference 
for a certain health status, to each disease and its associated manifestations. In theory, the 
utility of health status is best measured with choice-based methods which include 
uncertainty, such as the standard gamble method. Other choice-based methods, without 
uncertainty, include paired person-trade-off and time-trade-off techniques [19]. Utility 
measures are based on the fact that Paretian welfare economics requires that each 
individual be the judge of his or her own welfare. However, in practice, these methods are 
difficult to implement because different people have different reactions when faced with 
uncertainty and choices, especially when these are theoretical. For example, in the 
standard gamble method, the patients are asked to find the probability “p” at which they 
would be unable to choose between remaining in their current state of health or dying 
immediately with a probability of p (and living healthy with a probability of 1-p). Given 
the difficulty in implementing such measures, several groups of researchers have 
developed multi-attribute classification systems implemented in the form of scale-based 
 Novel Aspects on Cysticercosis and Neurocysticercosis 62 
questionnaires. Each answer to the scaled questions contributes a certain weight towards 
calculating utility. The utility weights are determined during studies where both the 
questionnaire and one of the choice-based methods are used, and then assumed to be 
generalizable to other contexts. Multi-attribute questionnaires are more commonly used 
than choice-based measures in QALYs studies. One advantage of multi-attribute 
questionnaires is that they may not only be used to estimate utility, but also to assess the 
perceptions of patients regarding different aspects of their health (i.e., mental, physical, 
social functioning, etc.).  
When used at a population level, QALYs combine quantitative estimates of death, 
frequency and duration of disease with a qualitative assessment of how well (or not) 
patients can live with the disease. In other words, rather than just counting the number of 
people with the disease, QALYs try to “adjust” for how well people can live with the 
disease. Therefore, QALYs are a product of life expectancy and a measure of the quality of 
remaining life years, with weights placed on time spent in different health states. Most 
preferable state receives more weight. A year of perfect health is worth 1 and a year of less 
than perfect health is worth less than 1. Death is considered to be equivalent to 0. 
However, some health states may be considered worse than death and have negative 
values [19]. 
The multi-attribute measurement scales most commonly used in developing countries, 
where NCC is endemic, are the Euro-Qol (EQ-5D) and the Short Form-12 (SF-12) [20, 21]. 
These tools provide patient-based determination of quality of life and can be used to 
compare perceptions of physical, mental, and social health among patients with different 
diseases (or lack of disease), different stages of the same disease, or before and after 
treatment of the disease. The latter approach is often used in clinical trials where a drug, 
while very effective in treating the disease, may be linked to numerous side effects which 
could lead to worse quality of life than the disease itself.  
The EQ-5D is a standardized measure of health status developed by the EuroQol Group. 
The EQ-5D questionnaire has 5 domains: mobility, self-care, usual activities, 
pain/discomfort, and anxiety/depression. For each domain, there are three levels of 
response: individuals are asked whether they have no problems, some problems, or severe 
problems. The answers to each domain are combined to generate a summary score, for a 
total of 125 possible combinations of answers, which indicates the overall utility. Table 1 
provides an example of utility scores that can be allocated to different combinations of 
answers to the five EQ-5D questions [22]. 
The SF-12 is another tool developed by Quality Metric Inc. to assess the quality of life of an 
individual at a given time. It uses 12 questions to measure eight domains of functional 
health and well-being namely physical functioning, role physical, bodily pain, general 
health, vitality, social functioning, role emotional, and mental health (Table 2) [21]. Physical 
and mental component summary scores can be calculated by aggregating the eight domains 
[23].  
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Description Utility 
score 
No problems 1.000 
No problems walking; no problems with self-care; some problems with 
performing usual activities; some pain or discomfort; not anxious or depressed 
0.760 
Some problems walking; some problems washing or dressing self; some 
problems with performing usual activities; moderate pain or discomfort; 
moderately anxious or depressed 
0.5616 
No problems walking; some problems washing or dressing self; unable to 
perform usual activities; some pain or discomfort; not anxious or depressed 
0.329 
Some problems walking; no problems with self-care; no problems with 
performing usual activities; moderate pain or discomfort; extremely anxious or 
depressed 
0.222 
Some problems walking; unable to wash or dress self; unable to perform usual 
activities; moderate pain or discomfort; moderately anxious or depressed 
0.079 
Confined to bed; unable to wash or dress self; unable to perform usual 
activities, extreme pain or discomfort; moderately anxious or depressed 
-0.429 
Table 1. Example of utility scores for the EQ-5D  
Domain Description
Physical functioning Degree to which health limits everyday physical activities 
Role physical Degree to which physical problems interfere with usual 
daily activities such as work or school 
Bodily pain  Degree of pain to the body 
General health Ratings of current health in general 
Vitality Ratings of energy level 
Social functioning Degree to which health interferes with social activities 
Role emotional Degree to which emotional problems interfere with usual 
daily activities such as school or work 
Mental health Degree to which health limits emotional well- being, 
including depression, anxiety and well being 
Table 2. Description of the health domains used in the SF-12 v2 quality of life survey 
Although QALYs are commonly used metrics in health economics, they also present some 
limitations. For example, adaptation of patients to certain symptoms may mask the impact 
of chronic disability. In addition, it is difficult to assign a single utility score to those diseases 
which cause a variety of clinical manifestations, such as NCC [24]. Another limitation is that 
scale-based measures can sometimes lead to “ceiling” or “flooring” effects where a majority 
of people consistently choose the “best” scenario or “worst” scenario. One important 
criticism of QALYs (which some view as an advantage), is that QALYs measures are 
subjective and not meant to be generalized to the society as a whole. QALYs associated with 
a disease in one country (or region) could not be used to estimate the burden in another 
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region (or country). For example, having epilepsy in the United States would have very 
different social and role functioning values than in Sub-Saharan Africa. This difficulty in 
using QALYs for international comparison led a group of researchers to develop a 
completely different type of metric for measuring burden: the DALY. 
3.2. Disability Adjusted Life Years (DALYs) 
DALYs were first constructed for the Global Burden of Disease (GBD) Study in order to 
provide a comparable measure of output for interventions, program and sector evaluations, 
and planning [25]. The GBD Study was conducted to evaluate the non-monetary burden of a 
variety of infectious and non-infectious conditions, as well as risk factors, on pre-defined 
regions of the world. The latest comprehensive assessment of the burden of diseases is for 
the year 2004. However, DALY estimates from the 2010 GBD Study are expected to be 
released in late 2012 [26]. The DALY is a summary measure of population health that 
assesses the disability and early mortality associated with the condition of interest. DALYs 
measure the gap in years between age at death and gender-specific average life expectancy 
in Japan and combines it with time lived in states other than excellent health (disabled). 
They are obtained by summing years of life lost (YLL) from premature death and healthy 
years lost due to disability (YLD). The formulas used for the calculation of YLL and YLD are 
described below: 
 YLL = N * L  (1) 
where N = number of deaths per age-sex group, L = remaining life expectancy at age of 
death 
 YLD = I * DW * D  (2) 
where I = age and sex specific estimates of incidence, DW = disability weight, D = average 
duration of disability.  
Disability weights are allocated according to the opinion of experts on how disabling a 
certain health status is perceived to be. Disability is placed on a uni-dimensional scale 
between 0 (perfect health) and 1 (death). In theory, utility is equal to 1-disability weight. 
Disability weights of clinical manifestations (referred to as indicator states) were determined 
for the original GBD Study by the person trade-off (PTO) method [27]. The PTO method is a 
way of estimating social preferences for different health states by asking people how many 
people affected by the health state of interest they would be willing to trade for extending 
the lives of 100 healthy people. This question is asked using two different formats. For the 
2010 GBD Study, community assessment of selected sequelae using discrete choice methods, 
assessment by health professionals of all sequelae using ranking and visual analog scale 
methods, and multi-method studies among highly educated respondents were utilized 
rather than the PTO method [28]. Results from the new disability weights have not yet been 
published. Examples of disability weights used to calculate DALYs for the original GBD 
Study are provided in table 3. 
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Degree of morbidity Disability 
weight 
Healthy 0 
Limited ability to perform at least one activity in one of the following 
areas: recreation, education, procreation or occupation 
0.096 
Limited ability to perform most activities in one of the following areas: 
recreation, education, procreation or occupation 
0.220 
Limited ability to perform most activities in two or more of the following 
areas: recreation, education, procreation or occupation 
0.400 
Limited ability to perform most activities in all of the following areas: 
recreation, education, procreation or occupation 
0.600 
Requires assistance with instrumental activities of daily living such as 
meal preparation, shopping or housework 
0.810 
Requires assistance with activities of daily living such as eating, personal 
hygiene or toilet use 
0.920 
Dead 1 
Table 3. Examples of disability weights used to calculate DALYs [25] 
Disability weights for NCC were not included in the original GBD study. However, in the 
2010 GDB estimates, NCC will be included as causing an average of 29% of all epilepsy 
cases in endemic countries. This estimate is based on a meta-analysis of the percentage of 
NCC lesions present in the brain of people with epilepsy [29]. Disability weights of epilepsy 
will be used as there is no clinical difference between NCC-associated and other types of 
epilepsy. As better estimates of the distribution of manifestations among NCC patients 
become available, more sequelae will be added to DALYs estimates associated with NCC. 
The only two available estimates of DALYs associated with NCC used the disability weights 
associated with epilepsy (both studies) and migraine (1 study) [30, 31]. 
The original GBD Study calculations considered two additional parameters: 1) discounting 
future time and 2) age weighting [25]. Discounting future time is a common concept in 
economic and social policy. In burden of disease estimations, a discount rate is applied so 
that future healthy life has less value than the net value of life today [27]. In the context of 
DALYs, a disability occurring today is worth more than the same disability occurring in the 
future. The subject of discounting is complex and several papers have been published in 
favor and against its use in the context of DALYs and health outcomes [27, 32]. By including 
age weighting, the original GBD Study incorporated social preferences for the value of life 
lived during adulthood over life lived during childhood or later years. However, the newest 
version of the GBD Study (the GBD 2010 Study) will not include age weighting in the 
DALYs calculations. Therefore, the influence of age weighting will be eliminated. 
The use of DALYs remains controversial, especially in measuring utilities. According to 
Anand (1997), DALYs understate the burden of disease of females relative to males since the 
standard expectation of life at birth in Japan is very similar in men and women [32]. DALYs 
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also measure the burden of disease without considering cultural or socioeconomic 
differentiation of tested populations so that it underestimates the disease burden in developing 
countries [33]. DALYs also go against Paretian welfare economics where each individual is the 
best judge of his or her own welfare. By using utility weights measured by people that are 
unaffected by the disease of interest, this concept is not respected. Even with these 
controversies, the DALY remains a widely used summary measure of population health.  
4. Measuring monetary burden  
Estimates of the monetary burden of zoonotic diseases that impact both human and 
livestock health should include assessment of both animal health costs and human health 
costs. The overall estimated cost can be calculated using the following equation: [34] 
 , , , , , ,
1 1 1
S A X
a s a s x a s x a s
s a x
N C 
  
           (3)  
This equation corresponds to the additive societal costs for all affected species (S) across all 
age groups (A). For the age-species-specific population of size (Na,s), with the age-species-
specific annual incidence (ßa,s), there is an age-species proportion (x,a,s,) of infected 
individuals with symptoms X. The treatment and consequences of each of these symptoms 
have a monetary burden of Cx,a,s. Ideally, the whole spectrum of symptoms and losses in 
humans and animals is included in the estimate [34].  
4.1. Human health costs 
Human health costs are classified into direct (health provider) and indirect (out-of-pocket) 
costs. Direct costs are costs associated with the diagnosis and treatment of patients. 
Commonly used diagnostic tests incorporated into direct costs include diagnostic imaging, 
sero-immunological and blood tests, and tests on cerebral spinal fluid (CSF). Diagnostic 
costs, for a neurological condition such as NCC, can be high since CT scans and MRI 
confirmatory tests are not readily available in developing countries and, if available, are 
often distantly located and expensive. Cost of treatment typically includes the cost of 
medicines, medical consultations, surgical charges, and hospital charges. In contrast to 
direct costs, indirect costs include costs of working days lost due to clinical manifestations or 
visits to hospitals, losses in productivity, buying over-the-counter drugs to relieve 
symptoms, costs of traditional treatment, and costs associated with transportation to and 
from medical treatment. Costs associated with the family members taking care of the 
patients would also need to be included. 
4.2. Animal health costs 
Animal health costs can be associated with partial or full condemnation of the carcass at 
slaughter or reduction in price of an infected carcass. The value of live animals can also be 
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reduced when, in the case of T. solium cysticercosis, reduction in the price of pigs due to the 
presences of cysts can lower a farmer’s household income. In addition, presence of T. solium 
in a country’s pig population results in restrictions on the export of pork products. 
4.3. Decision tree analysis 
Decision trees are very helpful in organizing the information gathered on the distribution of 
manifestations and treatment seeking pattern in the study population. They can also be used 
to incorporate the probability of receiving different types of diagnoses and treatments. The 
tree usually starts with a “trunk” which is the disease of interest (in the case of NCC, this 
can be epilepsy). From this trunk, a probability (chance node) corresponding to the 
frequency of the disease is used to create the first two “branches” of the tree: the presence or 
absence of the disease in the study population. Additional branches are added each time a 
new probability is added. Each probability (node) may lead to more than two branches. The 
end of each branch corresponds to the probability that a patient has of following a certain 
treatment/diagnosis path, including the path of not seeking any medical care. The 
probability of each branch of a path can be multiplied by the costs corresponding to the 
options in this branch. An example, the use of decision tree analysis to estimate losses due 
cysticercosis in South Africa is shown in Figure 1 [35]. In this example, for the branch of 
people with epilepsy who have NCC but do not seek medical attention, we would multiply 
1.33% by 36.7% by 70% to obtain the frequency of having NCC but not being treated (0.34%, 
as shown in Figure 1) [15, 36-41]. This percentage would be multiplied by the salary lost due 
to a reduction in productivity among people with epilepsy. Such trees can be developed for 
very complex treatment paths and for the impact of animal disease as well. 
 
Figure 1. Decision tree analysis tree for estimating the monetary burden of NCC in Eastern Cape 
Province, South Africa. Circle is a chance node and triangle is an end node [35]. 
4.4. Uncertainty and sensitivity analysis 
Common sources of epidemiological and economic data used in the assessment of disease 
burden include government and agency reports and values reported in the scientific 
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literature. Values for neglected zoonotic diseases, such as T. solium cysticercosis, are often 
underreported or else the method of collection might be biased. In short, exact estimates of 
these parameters are difficult to identify. Therefore, in order to account for uncertainties, the 
distribution of these parameters should be selected carefully. So, instead of using an exact 
value for each probability and cost value, a distribution of values is used to reflect 
uncertainty. To include these distributions into the final estimate, sampling methods such as 
the Monte Carlo or Latin Hypercube are often applied. The final estimate will itself be a 
distribution reflecting the uncertainty of all included parameters. Uniform distribution can 
be applied to parameters for which we have very limited knowledge. For example, instead 
of assuming that 1.33% of the population has epilepsy in the Eastern Cape Province of South 
Africa, we could assume that the prevalence lies anywhere between 0.5% and 2.8%, with an 
average at 1.33% [35]. The sampling method would start by sampling one value (for 
example, 1%) from this distribution, provide and save the estimate of the cost of NCC using 
this value. Next, another value would be sampled from the distribution and lead to another 
estimated cost, which will also be saved. This process is usually repeated up to 10,000 times 
until a distribution of the overall costs is obtained. The Latin Hypercube and Monte Carlo 
sampling methods are simply efficient tools of sampling several uncertain parameters 
iteratively.  
The sampling method described above will generate a database of 10,000 observations each 
associated with a different value for the uncertain parameters. We can then use linear 
regression using the estimated costs as the outcome and all of the uncertain parameters as 
“independent” variables to assess which parameters have the largest impacts on the 
estimated costs. The uncertain parameters with the largest impacts should be those that 
need to be better studied in the future because they have a strong influence on how much a 
disease costs a society. Sensitivity must be conducted with care to limit the values to those 
that are most likely and realistic. Including impossible values would lead to biased 
estimates and a false impression that they have an important impact on the overall cost 
estimate. 
5. Review of morbidity and mortality associated with neurocysticercosis 
There are only a few studies in the literature which report the distribution of manifestations 
among definitive or probable cases of NCC as defined by the Garcia and Del Brutto criteria 
(2005) [42]. The challenge in studying the natural history of NCC is that it is impossible to 
diagnose the presence of brain cysts without the use of imaging, and using radiation among 
a population without symptoms is unethical. Hence, the only information available is the 
distribution of manifestations among NCC patients that are already under care in facilities 
where imaging is available. This introduces a major selection bias which leads to likely 
overestimation of the frequency of more severe (and less stigmatizing) manifestations, or 
manifestations which are more likely to lead to a medical visit (and a referral to a clinic with 
imaging). In countries where epilepsy is stigmatized, people may be afraid to seek care 
which would lead to an underestimate of the distribution of epilepsy among people with 
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NCC. Similarly, people with cranial hypertension suffering from headaches may never seek 
medical attention. In contrast, people with hydrocephalus or stroke will most likely seek 
care.  
In a systematic review of studies conducted in clinics or hospitals with imaging facilities, the 
distribution of presenting symptoms among diagnosed NCC patients was as follows: 
seizures/epilepsy were the most common (78.8%, 95% CI: 65.1% - 89.7%) followed by 
headaches (37.9%, 95% CI: 23.3% - 53.7%), focal deficits (16.0%, 95% CI: 9.7% - 23.6%), and 
signs of increased intracranial pressure (11.7%, 95%CI: 6.0% - 18.9%) [8]. These results, 
though consistent with what is usually believed for NCC, may be biased by what presenting 
symptoms the clinicians assessed at admission. This systematic review of the literature also 
revealed that NCC may contribute to an important percentage of stroke cases in endemic 
areas. Unfortunately, to our knowledge, there is only one case-control study which has been 
conducted on this topic [10]. If NCC is truly linked to strokes, this could lead to a very 
important burden in endemic regions. 
The studies included in the systematic review described above were all clinical-based. There 
have also been several studies conducted in communities and small rural hospitals where, 
instead of sampling NCC cases, people with epilepsy received imaging for the diagnosis of 
NCC. When those studies were analyzed systematically, the percentage of people with 
epilepsy with lesions of NCC at imaging was 29% (95% CI: 23% - 36%) [29]. This finding is 
important as it suggests that nearly one third of all epilepsy cases living in endemic areas 
could possibly be prevented with appropriate control strategies. The measure of burden 
described above could help guide stakeholders as to which control strategy may lead to the 
best cost-utility or cost-benefit for their area. 
Compared to other helminthic infections, the socioeconomic burden of cysticercosis tends to 
be higher because the condition not only causes severe clinical manifestations, but can also 
result in mortality. Although limited data exist on NCC-related mortality, a study 
conducted in the United States and a study conducted in Brazil reported age-adjusted 
annual mortality rates of 0.06 (95% CI: 0.05 - 0.07) and 1.68 (95% CI: 1.58 - 1.78) deaths per 
million population, respectively [4, 43]. Additional studies from the U.S. states of California 
and Oregon reported crude mortality rates of 0.33 (95% CI: 0.27 - 0.38) and 0.29 (95% CI: 0.11 
- 0.64) deaths per million population, respectively [44, 45]. 
6. The monetary and non-monetary burden of neurocysticercosis 
Very few studies have been conducted to evaluate the burden of NCC. At present, two 
studies have been carried out in Africa evaluating the burden of cysticercosis/NCC. A study 
in West Cameroon revealed that 1.0% of the total population had NCC-associated epilepsy 
(based on serological results) and 5.6% of the pig population had cysticercosis [31]. Average 
number of DALYs lost due to NCC was 9.0 per 1,000 person-years and the monetary burden 
per case of NCC-associated epilepsy was 194 Euro in 2009. The total annual costs due to T. 
solium cysticercosis in West Cameroon were estimated at 10,255,202 Euro (95% CR 
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6,889,048–14,754,044), of which 4.7% were due to losses in pig husbandry and 95.3% to 
direct and indirect losses caused by human cysticercosis. This estimate only accounted for 
the disease burden due to NCC-associated epilepsy and used serology for the diagnosis of 
NCC.  
Similarly, another study conducted in the Eastern Cape Province of South Africa estimated 
that the monetary burden of NCC-associated epilepsy in 2004 varied from US$632 to US$844 
per case, indicating high financial losses associated with this condition [35]. The total 
number of estimated NCC-associated epilepsy cases was 34,662 (95% CI: 17,167 – 50,068) 
and among them, expert opinion and a review of the literature suggested that 70% of cases 
of epilepsy did not seek medical attention. Annual losses to the agricultural sector were 
estimated at US$5.0 million (95% CI: 2.4 – 8.1), with the overall monetary burden estimated 
at US$34.2 million (95% CI: 12.8 – 70.0) using the mean wage approach, US$20.1 million 
(95% CI: 9.6 – 35.3) using generalist replacement costs, and US$18.6 million (95% CI: 9.0 – 
32.3) using the traditional opportunity costs approach. 
A study conducted in Mexico showed that 0.25 DALY was lost per 1,000 person-years due to 
NCC-associated epilepsy and severe headaches, with NCC associated epilepsy responsible 
for 90% of this value [30]. According to 2004 GBD estimates, 1.7 DALYs per 1,000 person-
years were estimated to be lost due to epilepsy in Mexico, with approximately the same 
number of DALYs lost due to migraine. This indicates that almost 15% of DALYs lost due to 
epilepsy were associated with NCC. This study used only epilepsy and severe chronic 
headaches as clinical manifestations due to lack of frequency data and disability weights for 
other known clinical manifestations associated with NCC. Therefore, like the African 
studies, the total estimated number of DALYs lost was most likely underestimated.  
Three studies have been conducted to evaluate the quality of life of NCC patients. A study 
conducted at two tertiary neurology referral hospitals in Mexico City, Mexico indicated that 
NCC outpatients had significantly lower scores for each of the SF-12’s eight domains of 
health compared to an age-sex-hospital-day matched control group [46]. Similarly, a study 
conducted in Peru showed that patients with parenchymal NCC had decreased quality of 
life compared with healthy neighborhood controls and controls with epilepsy as measured 
by the short-form 36 (SF-36) quality of life survey [47]. In addition, a study conducted in 
Brazil showed the presence of depression had a significant impact on the quality of life of 
patients with NCC as measured by a direct subjective quantification scale and the 
Functional Assessment of Cancer Therapy Quality of Life Measurement System (FACT-HN 
version IV) [48]. 
7. Suggested methods to improve the burden assessment of 
neurocysticercosis 
While there are currently numerous ways in which to evaluate disease burden, each method 
has its pros and cons. Table 4 provides an overview of the established measures of disease 
burden currently available with which to evaluate the non-monetary or monetary burden of 
 
The Burden of Cysticercosis 71 
T. solium cysticercosis. While non-monetary burden metrics, such as the DALY, are most 
often used by international agencies, these metrics are not capable of capturing the burden of 
disease associated with animal infection. Therefore, in order to fairly compare the burden of 
cysticercosis with that of non-zoonotic diseases, studies need to be conducted to evaluate 
how cysticercosis in pigs affects individuals in endemic regions in terms of income/livelihood 
losses and social impact. This information can then be used to develop questions to 
incorporate into a QALY scale or else be added to DALYs to capture this burden. 
Measure 
of burden 
Items Availability / quality of data
 Humans Animals 
QALYs Cause specific death rates Quality highly variable 
between countries 
Not applicable 
Life expectancy Largely available 
Disease-specific incidence 
rates 
Notifiable / registry disease 
data  
Quality / completeness 
highly variable 
Time evolution of disease 
states 
 
Knowledge of natural 
history of disease needed 
Quality of life measure at 
various disease states 
 
Special studies  
Place / time specific 
DALYs Cause specific death rates Quality highly variable 
between countries 
Not applicable 
Disease-specific incidence 
rates 
Notifiable / registry disease 
data  
Quality / completeness 
highly variable 
Distribution of sequelae 
associated with disease in 
treatment free 
individuals 
Knowledge of natural 
history of disease needed 
Duration of each sequelae 
in treatment free 
individuals 
Knowledge of natural 
history of each sequelae 
needed 
Distribution of sequelae 
associated with disease 
among people under 
treatment 
Special studies required 
Duration of each sequelae 
under treatment 
Special studies required 
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Measure 
of burden 
Items Availability / quality of data
 Humans Animals 
Disability weights for 
each sequela (treated / 
non treated)  
Available from GBD 
initiative 
Not all sequelae have been 
attributed disability weights
Monetary 
burden 
Cause-specific death rates Quality highly variable 
between countries 
Rarely available except 
for notifiable diseases 
Disease-specific 
prevalence 
National / special survey 
data 
Special survey data often 
overestimate the truth 
Abattoir data where 
home slaughtering is 
rare 
Special survey data 
often overestimate the 
truth 
Distribution of sequelae 
associated with disease  
Knowledge of natural 
history of disease needed 
Knowledge of natural 
history of disease 
needed 
 
Frequency of care / 
treatments / diagnoses 
and productivity losses 
for each sequel 
 
Special studies 
Expert opinion 
Special studies 
Expert opinion 
Costs associated with 
care / treatments / 
productivity losses of 
each sequel 
Country-level health / labor 
statistics  
Special surveys 
Agricultural statistics 
Special surveys 
Table 4. Comparison of using QALYs, DALYs and monetary estimates to evaluate the disease burden 
of cysticercosis/NCC and other neglected zoonotic diseases with a livestock component [17] 
8. Conclusions 
T. solium cysticercosis is believed to contribute to high levels of human morbidity and some 
mortality, as well as pig production losses. This parasitic disease tends to disproportionately 
affect areas of low socio-economic status and should be prioritized for preventive measures 
because the disease is, in essence, 100% preventable. However, in order to make T. solium 
cysticercosis/NCC a priority condition, efforts to obtain more accurate estimates of disease 
burden must be made. In particular, a better understanding of the distribution of 
manifestations among all NCC cases would be very helpful. In addition, studies on the 
impact of NCC on productivity are needed. Such estimates could be used to show policy 
makers the true socioeconomic impact of this disease in various regions of the world. One of 
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the biggest limitations, for most of the measures of disease burden currently used for 
NCC/cysticercosis, is the lack of available high quality epidemiologic and/or financial data. 
Adherence to recommended guidelines for the diagnosis of cysticercosis in humans and 
pigs and declaring NCC a reportable disease would contribute greatly towards better 
burden estimates for this condition. 
9. Nomenclature 
Cysticercosis: Infection or disease of humans or animals caused by the larvae of Taenia spp. 
In this chapter, the term refers to infection of humans or pigs with Taenia solium. 
Decision tree analysis: A method of organizing epidemiological data into infections and the 
frequency of their consequences. 
Direct costs: Costs associated with the diagnosis and treatment of a medical condition, in 
addition to, costs associated with condemnation of all or part of an infected carcass.  
Disability Adjusted Life Year (DALY): A measure of overall disease burden, expressed as 
the number of years lost due to ill-health, disability, or early death. 
Disability weight: A score between 0 and 1 that is assigned to a condition depending on the 
degree of debilitation. 
Euro-Qol (EQ-5D): A standardized instrument for use as a measure of health outcome. 
Health Adjusted Life Year (HALY): An umbrella term for a family of measures of 
population health that includes, for example, Disability Adjusted Life Years (DALYs) and 
Quality Adjusted Life Year (QALYs). 
Indirect costs: Costs associated with lost wages or decreased productivity arising indirectly 
from infection. 
Neurocysticercosis (NCC): A neurological disease caused by invasion of the CNS by larvae 
of Taenia solium.  
Quality Adjusted Life Year (QALY): A measure of disease burden, including both the 
quality and the quantity of life lived. It is used in assessing the value for money of a medical 
intervention. A year of full health is equivalent to 1 QALY, whereas, death corresponds to 0 
QALYs. 
Short-Form 12 (SF-12): A generic dual (i.e., mental and physical health) scale measure of 
quality of life. 
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